Clinical trials: Advanced Solid Malignant Tumors
Advanced Solid Tumor, Non-Small Cell Lung Cancer
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05757492
- Testing
- CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Coherus Oncology, Inc.
Advanced or Metastatic Solid Tumors
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
A pharmacokinetic study to compare 2 clinical formulations of linifanib and the effect of food on the pharmacokinetics of linifanib.
- Trial name
- NCT01506934
- Testing
- linifanib
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Abbott
Solid Tumor
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors
- Trial name
- NCT07392736
- Testing
- AL8326 tablets, Toripalimab
- Where
- 15 sites in China
- Volunteers
- 228 people
- Sponsor
- Advenchen Laboratories, LLC
Solid Tumors
A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)
The main objectives of this trial are to determine the recommended dose of ridaforolimus for pediatric participants with advanced solid tumors by measuring the number of participants experiencing dose-limiting toxicities (DLTs)…
- Trial name
- NCT01431534
- Testing
- Ridaforolimus
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Breast Cancer
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
The study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe the safety， tolerability and efficacy of FS-1502.
- Trial name
- NCT03944499
- Testing
- FS-1502
- Where
- 12 sites in China
- Volunteers
- 161 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Solid Tumor
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX…
- Trial name
- NCT00502567
- Testing
- AZD2171, FOLFOX, Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Advanced Solid Tumor
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration
- Trial name
- NCT03457532
- Testing
- Gumarontinib Tablets
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Advanced Solid Tumors or Lymphoma
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of recombinant humanized anti- PD-1 monoclonal antibody（SCT-I10A）in patients with advanced solid tumors or lymphoma…
- Trial name
- NCT03821363
- Testing
- SCT-I10A
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sinocelltech Ltd.
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Non-small Cell Lung Cancer
A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors
This is a phase I/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of BPI-361175 tablets in patients with advanced solid tumors including advanced Non-small cell Lung cancer…
- Trial name
- NCT05329298
- Testing
- BPI-361175
- Where
- 8 sites in China
- Volunteers
- 90 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Malignant Neoplasms
Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors
Phase I study of YKYY031 for injection in patients with advanced solid tumors
- Trial name
- YKYY031，tumors (NCT07631793)
- Testing
- YKYY031 group (the first stage), YKYY031 group (the second stage)
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor Cancer
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection.
- Trial name
- NCT04389281
- Testing
- X-PACT
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Immunolight, LLC
Advanced Solid Tumor, Advanced Lymphoma
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid…
- Trial name
- NCT05279300
- Testing
- CS5001, Rituximab, Gemcitabine
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 480 people
- Sponsor
- CStone Pharmaceuticals
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Solid Tumor
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.
- Trial name
- NCT03757936
- Testing
- HLX04, HLX10
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Henlius Biotech
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Advanced Solid Tumors
A Study of KM501 in Patients With Solid Tumors
A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate…
- Trial name
- NCT05804864
- Testing
- KM501
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Pan Tumor
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
The purpose of this study is to demonstrate the clinical activity of nivolumab in combination with ipilimumab in multiple types of tumors based on their Tumor Mutational Burden status.
- Trial name
- CheckMate 848 (NCT03668119)
- Testing
- Nivolumab, Ipilimumab
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
This is a 3-cohort, multicenter, Phase 1 study of the effect of tesetaxel, an investigational, orally administered taxane, on the corrected QT (QTc) interval and the potential effect of food, a cytochrome P450 (CYP) 3A inhibitor…
- Trial name
- NCT04312282
- Testing
- Tesetaxel, Itraconazole, Rifampin
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Odonate Therapeutics, Inc.